Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891197 · ClinicalTrials.gov registry record
A Biomarker Screening Protocol for Participants With Solid Tumors
A clinical trial, sponsored by Lyell Immunopharma.
- Terminated
- Registry status
- 10
- Enrollment target
NCT05891197 is a clinical trial that was terminated before completion, run by Lyell Immunopharma. The registered enrollment target is 10 participants.
The verdict
NCT05891197 was terminated before completion, sponsored by Lyell Immunopharma.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. Fresh tumor biopsies are not permitted on this study. The study will be conducted virtually and participants will utilize telehealth and e-consent modules. If participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. Participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-19 |
| Est. Completion | 2025-02-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891197
The ClinicalTrials.gov registry entry for NCT05891197 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lyell Immunopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05891197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05891197 about?
NCT05891197 is a clinical study titled "A Biomarker Screening Protocol for Participants With Solid Tumors". Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may info...
What is the current status of trial NCT05891197?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2023-05-19. Estimated completion is 2025-02-05.
Who is sponsoring clinical trial NCT05891197?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.